AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9731680 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass with 250 cm limb for BMI ≥ 51 kg/m2 (n = 6)
Number of subjects: 60
Study 8015757 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0
Study 8015757 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed placement of epidural until 5 cm cervical dilatation or greater
Number of subjects: 0
Study 2538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous radiation and chemotherapy (group 1)
Number of subjects: 135
Study 2538962 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy followed by radiation (group 2)
Number of subjects: 135
Study 2538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study 2538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission patients
Number of subjects: 135
Study 2538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy responders in group 2
Number of subjects: 135
Study 30947092 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatization Disorder (SD)
Number of subjects: 422
Study 30947092 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-clinical factors
Number of subjects: 422
Study 28756830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic allergies
Number of subjects: 382
Study 28756830 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings on packages
Number of subjects: 382
Study 28756830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to quit in 2 months
Number of subjects: 382
Study 28756830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine dependent smokers
Number of subjects: 382
Study 28756830 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-motivated smokers
Number of subjects: 382
Study 25598105 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal esophageal dissection and mobilization (MAX)
Number of subjects: 0
Study 25598105 — intervention group
Group type: COMPARATOR
Intervention: Minimal esophageal dissection and mobilization (MIN)
Number of subjects: 0
Study 25008011 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia reticulata and Vitamin D₃ (200 mg of Salacia reticulata and 1.6 µg Vitamin D₃ 3 times/day with meals)
Number of subjects: 40
Study 25008011 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle and fitness training for 4 weeks
Number of subjects: 40
Study 21808660 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in pitch
Number of subjects: 0
Study 21808660 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in volume
Number of subjects: 0
Study 21808660 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic auditory processes
Number of subjects: 0
Study 21808660 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological processes encoding sound pitch and intensity
Number of subjects: 0
Study 18516403 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg/qd (n=11)
Number of subjects: 22
Study 18516403 — intervention group
Group type: COMPARATOR
Intervention: No spironolactone (n=11)
Number of subjects: 22
Study 16873329 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed dental scaling instruments with a large diameter (10 mm) and light weight (15 g)
Number of subjects: 24
Study 16873329 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed dental scaling instruments with diameters larger than 10 mm
Number of subjects: 24
Study 16873329 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed dental scaling instruments lighter than 15 g
Number of subjects: 24
Study 12615252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium 15 mmol twice daily (Magnosolv‐Granulat, total magnesium 365 mg provided as magnesium citrate)
Number of subjects: 187
Study 12615252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 11234440 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive-fluoridated water (group A)
Number of subjects: 27
Study 11234440 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of steam and aerosol using municipal drinking water (group C)
Number of subjects: 27
Study 11234440 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive-fluoridated waters (group B)
Number of subjects: 27
Study 8868018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone regimen
Number of subjects: 59
Study 8868018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 1519685 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal anti-inflammatory gel
Number of subjects: 50
Study 1519685 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study 6389647 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.025 micrograms/kg/min)
Number of subjects: 6
Study 6389647 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 30194849 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) patch
Number of subjects: 4011
Study 30194849 — intervention group
Group type: COMPARATOR
Intervention: No GTN patch
Number of subjects: 4011
Study 30194849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment continued
Number of subjects: 4011
Study 30194849 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment stopped
Number of subjects: 4011
Study 27725887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (treadmill walking for as long as possible)
Number of subjects: 20
Study 27725887 — intervention group
Group type: COMPARATOR
Intervention: Precision Training (walking precisely over obstacles and onto targets overground)
Number of subjects: 20
Study 27725887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training
Number of subjects: 20
Study 27725887 — intervention group
Group type: COMPARATOR
Intervention: Precision Training
Number of subjects: 20
Study 24682001 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor group (n = 10) watched a humorous video for 20 min.
Number of subjects: 20
Study 24682001 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) sat calmly for 20 min without distractions.
Number of subjects: 20
Study 23404432 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior medical student-directed suture skills' training
Number of subjects: 48
Study 23404432 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced faculty surgeon-directed suture skills' training
Number of subjects: 48
Study 23404432 — intervention group
Group type: COMPARATOR
Intervention: Self-directed suture training (control)
Number of subjects: 48
Study 21080972 — intervention group
Group type: EXPERIMENTAL
Intervention: QUIT-PRIMO intervention (e-referral with paper information-prescription referral)
Number of subjects: 160
Study 21080972 — intervention group
Group type: COMPARATOR
Intervention: Standard patient smoking cessation website
Number of subjects: 160
Study 21080972 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented patient smoking cessation website (with access to a tobacco treatment specialist online, motivational emails, and an online support group)
Number of subjects: 160
Study 18648199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 3 months
Number of subjects: 152
Study 18648199 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 152
Study 16965911 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 30
Study 16965911 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 12834860 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivudin 1 x 125 mg for 7 days
Number of subjects: 1227
Study 12834860 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 5 x 800 mg for 7 days
Number of subjects: 1227
Study 10230711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-rich drink (2 g tyrosine, 5 daily doses)
Number of subjects: 21
Study 10230711 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich drink (same calories, 255 kcal)
Number of subjects: 21
Study 10230711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-rich drink
Number of subjects: 21
Study 10230711 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich drink
Number of subjects: 21
Study 8917032 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple frequency bioimpedance
Number of subjects: 8
Study 8917032 — intervention group
Group type: EXPERIMENTAL
Intervention: Single frequency bioimpedance
Number of subjects: 8
Study 1871541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 16
Study 1871541 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg twice daily)
Number of subjects: 16
Study 6688261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 34
Study 6688261 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 34
Study 3914014 — intervention group
Group type: EXPERIMENTAL
Intervention: Merck‐Sharp and Dohme pneumococcal vaccine (14 serotypes)
Number of subjects: 1686
Study 3914014 — intervention group
Group type: COMPARATOR
Intervention: Reference group (not vaccinated)
Number of subjects: 1686
Study 31221935 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied 2 times per day for 4 weeks (total of 56 sessions) at P6-Lu1-Lu10 acupuncture points.
Number of subjects: 0
Study 31221935 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 0
Study 29796918 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based self-training with CAD as second reader
Number of subjects: 20
Study 29796918 — intervention group
Group type: COMPARATOR
Intervention: Computer-based self-training without CAD
Number of subjects: 20
Study 27433096 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hemocoagulase spray
Number of subjects: 89
Study 27433096 — intervention group
Group type: COMPARATOR
Intervention: Traditional 8% norepinephrine spray
Number of subjects: 89
Study 23886594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN)
Number of subjects: 485
Study 23886594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 485
Study 23886594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (HCTZ and ATEN)
Number of subjects: 485
Study 23886594 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 485
Study 21975176 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy vaccination (specific immunotherapy)
Number of subjects: 27
Study 21975176 — intervention group
Group type: EXPERIMENTAL
Intervention: Alder pollen allergy (natural exposure)
Number of subjects: 27
Study 21975176 — intervention group
Group type: COMPARATOR
Intervention: Nonallergic subjects
Number of subjects: 27
Study 18805604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low relative CHD risk
Number of subjects: 375
Study 18805604 — intervention group
Group type: COMPARATOR
Intervention: High relative CHD risk
Number of subjects: 375
Study 18850029 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive environment
Number of subjects: 20
Study 18850029 — intervention group
Group type: COMPARATOR
Intervention: Negative environment
Number of subjects: 20
Study 15725286 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% MDBGN applied once daily
Number of subjects: 31
Study 15725286 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% MDBGN applied 4 times daily
Number of subjects: 31
Study 15725286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MDBGN exposure)
Number of subjects: 31
Study 12574098 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 16
Study 12574098 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 16
Study 12574098 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan
Number of subjects: 16
Study 12574098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10383522 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 122
Study 10383522 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 250 mg b.d.)
Number of subjects: 122
Study 8710739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rac-talinolol 30 mg i.v. and 100 mg p.o. in cholecystectomized patients
Number of subjects: 12
Study 8710739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rac-talinolol 25 mg, 50 mg, 100 mg, and 400 mg p.o. in healthy volunteers
Number of subjects: 12
Study 8710739 — intervention group
Group type: EXPERIMENTAL
Intervention: Caco-2 cell monolayers permeability study with rac-talinolol concentrations from 0.1 to 2.0 mM
Number of subjects: 12
Study 8710739 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil at 0.5 mM added to Caco-2 cell studies
Number of subjects: 12
Study 1987387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg) + Dipyridamole (150 mg)
Number of subjects: 549
Study 1987387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 6352081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (240,000 IU over 1 hr)
Number of subjects: 51
Study 6352081 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (500,000 IU over 15 min)
Number of subjects: 51
Study 6352081 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (1 million IU over 45 min)
Number of subjects: 51
Study 6352081 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 51
Study 6352081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 51
Study 30835309 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 300
Study 30835309 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 28856435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of triamcinolone
Number of subjects: 143
Study 28856435 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan GF20
Number of subjects: 143
Study 28856435 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone + hylan GF20
Number of subjects: 143
Study 28856435 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study 26378739 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive digital games
Number of subjects: 0
Study 26378739 — intervention group
Group type: COMPARATOR
Intervention: Passive digital games
Number of subjects: 0
Study 26378739 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive conditions
Number of subjects: 0
Study 26378739 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed player perceived as similar
Number of subjects: 0
Study 24118079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 mg
Number of subjects: 2570
Study 24118079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg
Number of subjects: 2570
Study 24118079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study 24118079 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 2570
Study 21272053 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 242
Study 21272053 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod
Number of subjects: 242
Study 21272053 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 242
Study 18654082 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day) - fully informed group
Number of subjects: 114
Study 18654082 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day) - partially informed group
Number of subjects: 114
Study 18654082 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day) - not informed group
Number of subjects: 114
Study 18654082 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (20 mg)
Number of subjects: 114
Study 18654082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 16202184 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 39
Study 16202184 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol + Phenytoin
Number of subjects: 39
Study 16202184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Haloperidol + Placebo)
Number of subjects: 39
Study 16202184 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 39
Study 15387395 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplicate Prescription Program (TPP) in New York
Number of subjects: 125837
Study 15387395 — intervention group
Group type: COMPARATOR
Intervention: No intervention (New Jersey Medicaid)
Number of subjects: 125837
Study 11491176 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 0
Study 11491176 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 0
Study 9200860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxur exposure at 50% relative humidity
Number of subjects: 0
Study 9200860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxur exposure at 70% relative humidity
Number of subjects: 0
Study 9200860 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxur exposure at 90% relative humidity
Number of subjects: 0
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of less than 15 cigarettes per day
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 15-24 cigarettes per day
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age < 45)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age 45-54)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age 55-64)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (age 65 or over)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (women)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (lowest cholesterol tertile)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (no history of diabetes)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (no hypertension)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (no family history of ischaemic heart disease)
Number of subjects: 2022
Study 7843337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 25 or more cigarettes per day (low body mass index)
Number of subjects: 2022
Study 3127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 1 mg
Number of subjects: 8
Study 3127243 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg
Number of subjects: 8
Study 3127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride lower doses
Number of subjects: 8
Study 3127243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31664920 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 gene‐centric score (GS)
Number of subjects: 79578
Study 31664920 — intervention group
Group type: COMPARATOR
Intervention: PCSK9 inhibitors
Number of subjects: 79578
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 daily
Number of subjects: 279
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 2-weekly
Number of subjects: 279
Study 28231782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 daily
Number of subjects: 279
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 2-weekly
Number of subjects: 279
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 4-weekly
Number of subjects: 279
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/D3
Number of subjects: 279
Study 28231782 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 and D3
Number of subjects: 279
Study 25979180 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based sleep education programme (four classroom lessons delivered weekly)
Number of subjects: 296
Study 25979180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 296
Study 23448270 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein markers in blood (total, free and intact PSA, kallikrein-related peptidase 2)
Number of subjects: 3654
Study 23448270 — intervention group
Group type: COMPARATOR
Intervention: Clinical tests (including DRE and TRUS volume)
Number of subjects: 3654
Study 23448270 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein markers with DRE or DRE plus TRUS volume
Number of subjects: 3654
Study 23448270 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein markers
Number of subjects: 3654
Study 22047843 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-cue condition
Number of subjects: 166
Study 22047843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting condition
Number of subjects: 166
Study 22047843 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 166
Study 20956120 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Number of subjects: 0